



21st December 2021

To Whom it may concern;

CT2394/2020-Tender for The Supply of Hydrocortisone Tablets.

We wish to respond to the objection raised by Health House Pharma Ltd. against our award of the above-mentioned tender. Between 14th June 2021 until the withdrawal of the award in December 2021, Health House Pharma apparently didn't follow up their original email to gain a response at any point, using any other means of communication, or via an alternative contact.

1. The contract could have been amended to state that it could not have been registered due to the origin of the product; or a statement could have been provided at the time of returning the contract to the same affect.
2. The final point, to which they state they were not given adequate information as to whether they could sign the contract, isn't a valid reason for not returning contracts. As all economic operators (especially those based in the UK) are aware of the restrictions surrounding quoting for, supplying and registering UK products in Malta after 31/01/2020. As they mentioned themselves, they are aware of the "overriding conditions post Brexit and post 1 January 2021"

We also wish to add that due to the time that has passed since the original tender deadline date of 12th November 2020, we would now also be able to supply an alternative EU licensed product at the same terms as our original quoted product. If this option is preferable then we would register as per the relevant tender conditions.

Regards

A handwritten signature in black ink, appearing to be "CP" or similar initials.

Chris Powell
International Sales & Development Manager